Caricamento...
The synergistic inhibitory effect of combining therapies targeting EGFR and mitochondria in sarcomas
Our group previously demonstrated that sarcoma cell lines were insensitive to epidermal growth factor receptor (EGFR) inhibitor gefitinib monotherapy. PENAO, an anti-tumour metabolic compound created in our laboratory, is currently in clinical trials. Considering the positive regulation of tumour en...
Salvato in:
| Pubblicato in: | Oncotarget |
|---|---|
| Autori principali: | , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Impact Journals LLC
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6967775/ https://ncbi.nlm.nih.gov/pubmed/32002123 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.27416 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|